Solifenacin at 3 years: A review of efficacy and safety

Postgraduate Medicine

Volumn 120, Issue 2, 2008, Pages 85-91

  Pelman, Richard S ^a   Capo' Jr , James P ^b   Forero Schwanhaeuser, Sergio ^c  

^a Bellevue Urology Associates   (United States)

^b Internal Medicine Associates of Atlanta   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

Overactive bladder; Solifenacin; Urge urinary incontinence; VESIcare

Indexed keywords

ATAZANAVIR; DILTIAZEM; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; LOPINAVIR PLUS RITONAVIR; PLACEBO; RITONAVIR; SOLIFENACIN; TOLTERODINE; VERAPAMIL; VORICONAZOLE; MUSCARINIC RECEPTOR BLOCKING AGENT; QUINUCLIDIN 3' YL 1 PHENYL 1,2,3,4 TETRAHYDROISOQUINOLINE 2 CARBOXYLATE MONOSUCCINATE; QUINUCLIDIN-3'-YL-1-PHENYL-1,2,3,4-TETRAHYDROISOQUINOLINE-2-CARBOXYLATE MONOSUCCINATE; QUINUCLIDINE DERIVATIVE; TETRAHYDROISOQUINOLINE DERIVATIVE;

ABDOMINAL PAIN; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; BLURRED VISION; CLINICAL TRIAL; CONSTIPATION; COUGHING; DEPRESSION; DIZZINESS; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRY EYE; DYSPEPSIA; FATIGUE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; INFLUENZA; MYCOSIS; NAUSEA; OVERACTIVE BLADDER; PERIPHERAL EDEMA; PHARYNGITIS; URGE INCONTINENCE; URINARY TRACT INFECTION; URINE RETENTION; VOMITING; XEROSTOMIA; ADOLESCENT; ADULT; AGED; DRUG ADMINISTRATION; MIDDLE AGED; PATHOPHYSIOLOGY; REVIEW; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DRUG ADMINISTRATION SCHEDULE; HUMANS; MIDDLE AGED; MUSCARINIC ANTAGONISTS; QUINUCLIDINES; TETRAHYDROISOQUINOLINES; TREATMENT OUTCOME; URINARY BLADDER, OVERACTIVE;

EID: 54049098877     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2008.07.1795     Document Type: Article

References (18)

1. Hegde SS. Muscarinic receptors in the bladder: from basic research to therapeutics. Br J Pharmacol. 2006;147(suppl 2):S80-S87. (Pubitemid 43237576)
2. Brunton S, Kuritzky L, Recent developments in the management of overactive bladder: focus on the efficacy and tolerability of once daily solifenacin succinate 5 mg. Curr Med Res Opin. 2005;21(1):71-80. (Pubitemid 40327507)
3. Chapple CR, Cardozo L, Steers WD, Govier FE. Solifenacin significantly improves all symptoms of overactive bladder syndrome. Int J Clin Pract. 2006;60(8):959-966. (Pubitemid 44082287)
4. Staskin D, Dmochowski R, Serels S, Andoh M, Hussain I, Smith N. Report from a randomized, placebo-controlled study showing significant improvement in urgency and patient-reported outcomes in overactive bladder patients treated with solifenacin. Int Urogynecol J. 2007;18(suppl 1):S73.
5. Chapple CR, Martinez-Garcia R, Selvaggi L, et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol. 2005;48(3):464-470. (Pubitemid 41188406)
6. Wagg A, Wyndaele JJ, Sieber P. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: A pooled analysis. Am J Geriatr Pharmacother. 2006;4(1):14-24. (Pubitemid 43758181)
7. Staskin DR, MacDiarmid SA. Pharmacologic management of overactive bladder: practical options for the primary care physician. Am J Med. Mar 2006;119(3 suppl 1):24-28. (Pubitemid 43227970)
8. Haab F, Cardozo L, Chapple C, Ridder AM. Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. Eur Urol. 2005;47(3):376-384. (Pubitemid 40248865)
9. Chapple CR, Arano P, Bosch JL, De Ridder D, Kramer AE, Ridder AM. Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study. BJU Int. 2004;93(1):71-77. (Pubitemid 38112970)
10. VESIcare [package insert]. Deerfield, IL: Astellas Pharma, US, Inc.; 2005.
11. Smulders RA, Kuipers ME, Krauwinkel WJ. Multiple doses of the antimuscarinic agent solifenacin do not affect the pharmacodynamics or pharmacokinetics of warfarin or the steady-state pharmacokinetics of digoxin in healthy subjects. Br J Clin Pharmacol. 2006;62(2):210-217. (Pubitemid 44316432)
12. Taekema-Roelvink ME, Swart PJ, Kuipers ML, Krauwinkel WJ, Visser N, Smulders RA. Pharmacokinetic interaction of solifenacin with an oral contraceptive containing ethinyl estradiol and levonorgestrel in healthy women: a double-blind, placebo-controlled study. Clin Ther. 2005;27(9):1403-1410. (Pubitemid 41598371)
13. Krauwinkel WJ, Smulders RA, Mulder H, Swart PJ, Taekema-Roelvink ME. Effect of age on the pharmacokinetics of solifenacin in men and women. Int J Clin Pharmacol Ther. 2005;43(5):227-238. (Pubitemid 40668446)
14. Andersson KE, Antimuscarinics for treatment of overactive bladder. Lancet Neurol. 2004:3(1):46-53. (Pubitemid 38018927)
15. Kuipers M, Smulders R, Krauwinkel W, Hoon T. Open-label study of the safety and pharmacokinetics of solifenacin in subjects with hepatic impairment. J Pharmacol Sci. 2006;102(4):405412. (Pubitemid 44954600)
16. Astellas Pharma US, Inc. Astellas Worldwide Market Authorization Status. June 2007.
17. Astellas Pharma US, Inc. Astellas internal data, IMS MIDAS Global Sales Audit, IMS KPA, SDI (Surveillance Data Inc.) patient longitudinal data, from August 2004 to March 2007.
18. Dresser GK, Bailey DG. A basic conceptual and practical overview of interactions with highly prescribed drugs. Can J Clin Pharmacol. Winter 2002;9(4):1991-1998. (Pubitemid 36903538)